Statements (88)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:activities |
inhibits sodium-glucose cotransporter 2
|
| gptkbp:approves |
gptkb:legislation
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Farxiga
|
| gptkbp:category |
gptkb:unknown
gptkb:C Category C |
| gptkbp:class |
gptkb:drug
|
| gptkbp:clinical_trial |
Phase III
long-term management as an adjunct to diet and exercise adjunct to diet and exercise in combination with other antidiabetic agents |
| gptkbp:contraindication |
dialysis
end-stage renal disease severe renal impairment hypersensitivity to dapagliflozin |
| gptkbp:dosage_form |
gptkb:tablet
10 mg 5 mg |
| gptkbp:effective_date |
January 2014
2014-01-09 |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:tablet
film-coated tablet |
| gptkbp:has_ability |
10 mg
5 mg |
| gptkbp:healthcare |
gptkb:theorem
|
| https://www.w3.org/2000/01/rdf-schema#label |
Farxiga
|
| gptkbp:ingredients |
gptkb:dapagliflozin
|
| gptkbp:interacts_with |
gptkb:Company
diuretics other antidiabetic agents sulfonylureas |
| gptkbp:invention |
2028
2028-10-20 |
| gptkbp:is_used_for |
heart failure
chronic kidney disease type 2 diabetes treatment of type 2 diabetes |
| gptkbp:lifespan |
12.9 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:2014 gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
renal
|
| gptkbp:pharmacokinetics |
bioavailability 78%
|
| gptkbp:population |
adults
adults with type 2 diabetes adults with heart failure adults with chronic kidney disease children over 10 years old |
| gptkbp:price |
varies by location
varies by insurance approximately $500 per month |
| gptkbp:products |
gptkb:Invokana
gptkb:Jardiance Steglatro |
| gptkbp:provides_information_on |
ADA Standards of Medical Care
AACE Guidelines recommended in ADA guidelines recommended in EASD guidelines |
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:research_focus |
long-term safety
weight loss effects renal outcomes cardiovascular outcomes |
| gptkbp:safety_features |
risk of bladder cancer
risk of bone fractures risk of ketoacidosis |
| gptkbp:scholarships |
stay hydrated
consult healthcare provider before use monitor blood sugar levels report signs of infection monitor kidney function |
| gptkbp:side_effect |
dehydration
hypotension urinary tract infections kidney problems genital mycotic infections |
| gptkbp:storage |
room temperature
|